Drug intelligence / Profile preview

QLS-1128

Development stage: Phase 3
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QLS-1128 is an orally available small molecule antiviral drug developed by Qilu Pharmaceutical. It acts as a selective inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), also known as the main protease, which is essential for viral replication. The drug is being investigated primarily for the treatment of COVID-19 and has reached Phase 3 clinical trials in symptomatic patients with mild to moderate disease. Its mechanism targets a key enzyme required for coronavirus polyprotein processing, thereby inhibiting viral replication[1][2][7].

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on QLS-1128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS-1128.

Explore the full profile